Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Sanara MedTech's operating assets for the quarter that ended in Mar. 2026 was $55.7 Mil. Sanara MedTech's operating liabilities for the quarter that ended in Mar. 2026 was $13.9 Mil. Sanara MedTech's Total Assets for the quarter that ended in Dec. 2025 was $72.9 Mil. Therefore, Sanara MedTech's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.57.
Sanara MedTech Scaled Net Operating Assets Related Terms
Sanara MedTech Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Sanara MedTech's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SMTI vs EMBC, KRMD, UTMD: Scaled Net Operating Assets Comparison
For the Medical Instruments & Supplies subindustry, Sanara MedTech's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanara MedTech Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Sanara MedTech's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.57 mean?
Sanara MedTech (SMTI) has a Scaled Net Operating Assets of 0.57 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sanara MedTech and its competitors.
Is Sanara MedTech's Scaled Net Operating Assets too high?
Sanara MedTech's current Scaled Net Operating Assets is 0.57. Overall, Sanara MedTech has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's Scaled Net Operating Assets compare to EMBC and KRMD?
Sanara MedTech's Scaled Net Operating Assets of 0.57 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sanara MedTech and its competitors. Sanara MedTech's current Scaled Net Operating Assets is 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.54, compared to a current price of $23.45 — trading 48.5% below its estimated fair value. The current Scaled Net Operating Assets is 0.57. Sanara MedTech's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current Scaled Net Operating Assets is 0.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanara MedTech (SMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued.
The current stock price of $23.45 is trading 48.5% below its estimated GF Value™ of $45.54.
GuruFocus considers Sanara MedTech to be Possible Value Trap.
Key valuation signals for SMTI:
Scaled Net Operating Assets: 0.57
GF Value™: $45.54 vs. price of $23.45 (48.5% below fair value)
No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
72GF Score
Get the complete analysis for SMTI
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMTI has been successfully added to your 
